PRESS RELEASE
News
-
-
PRESS RELEASE
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases -
-
-
PRESS RELEASE
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia (fitusiran) approved as the first US therapy for hemophilia A or B with or without inhibitors, offering consistent protection with few injections, using unique mechanism to reduce bleeding episodes -
PRESS RELEASE
Communiqué de presse : Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs
La FDA approuve Qfitlia, premier médicament pour hémophilies A/B. Protection contre saignements. Taux d'antithrombine abaissé. Mécanisme unique. Qfitlia réduit doses. Disponible en stylo ou flacon -
-
-
PRESS RELEASE
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD -
PRESS RELEASE
Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO
Le Dupixent est le premier biomédicament approuvé au Japon pour traiter la BPCO, avec des résultats positifs provenant d'études de phase III. Paris, New York - 28 mars 2025
